The National Cancer Institute (NCI) and ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) wish to identify correlative studies that incorporate the use of a validated test system for circulating tumor DNA analysis (ctDNA analysis) that is suitable for testing of blood specimens collected from nearly 6000 patients in the NCI-MATCH / EAY131 clinical trial. These specimens represent a valuable and irreplaceable resource.
NCI-MATCH / EAY131 is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. NCI-MATCH was co-developed by ECOG-ACRIN and the NCI. It is being led by ECOG-ACRIN through its Biomarker Sciences Program.
This announcement requests proposals to use blood specimens from the trial to answer diagnostic and translational questions. NO funding will be awarded, but rather awardees will be given access to a subset of NCI-MATCH blood specimens. Applicants are expected to utilize their own funding for the proposed assay and data analysis of the requested blood specimens. The investigator’s funding is also required to support the costs incurred by the biobank for pulling and distributing the specimens for analysis.
Send an email to the NCI project team.